| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Children's Hospital, Ludwig Maximilians University of Munich, Munich, Germany
CORRESPONDENCE: M. Griese, Children's Hospital, Dr. von Hauner Kinderspital, Lindwurmstr. 4, D-80337, München, Germany. Fax: 49 8951607872. E-mail: mgriese@helios.med.uni-muenchen.de
Keywords: allergic bronchopulmonary aspergillosis, cystic fibrosis, surfactant protein D
Received: May 30, 2003
Accepted June 22, 2003
Surfactant protein D (SP-D) interacts with Aspergillus fumigatus and is strongly increased in the lavage from animals with acute allergic reactions to the fungus, suggesting a central role for SP-D. As the course of cystic fibrosis (CF) is often complicated by an allergic bronchopulmonary aspergillosis (ABPA), the authors hypothesised that SP-D may also be increased in serum during an ABPA, potentially assisting in its diagnosis and follow-up.
In 22 patients with CF (11 with ABPA, 11 matched without ABPA) and 19 control patients without a pulmonary disease, SP-D concentrations in serum were assessed by an enzyme immunoassay.
Serum SP-D in CF patients (130±16 ng·mL–1 (mean±sem)) was significantly higher than in the controls without lung disease (66±8 ng·mL–1). During the whole ABPA-episode, SP-D level did not change significantly, despite large changes of total serum immunoglobulin E. There was a clear negative correlation between SP-D concentration and overall lung function, i.e. forced expiratory volume in one second and forced vital capacity.
Serum level of surfactant protein D may be of value to follow pulmonary function and lung injury in cystic fibrosis patients. Surfactant protein D serum levels are not helpful for the diagnosis and follow-up of an allergic bronchopulmonary aspergillosis episode, contrary to what was expected from animal experiments.
This article has been cited by other articles:
|
|
 |
|
  D. D. Sin, S. F. P. Man, D. D. Marciniuk, G. Ford, M. FitzGerald, E. Wong, E. York, R. R. Mainra, W. Ramesh, L. S. Melenka, et al. The Effects of Fluticasone with or without Salmeterol on Systemic Biomarkers of Inflammation in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1207 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. D. Sin, P. S. Pahlavan, and S.F. P. Man Review: Surfactant protein D: A lung specific biomarker in COPD? Therapeutic Advances in Respiratory Disease, April 1, 2008; 2(2): 65 - 74. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Latzin, D. Hartl, N. Regamey, U. Frey, M. H. Schoeni, and C. Casaulta Comparison of serum markers for allergic bronchopulmonary aspergillosis in cystic fibrosis Eur. Respir. J., January 1, 2008; 31(1): 36 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hartl, P. Latzin, G. Zissel, M. Krane, S. Krauss-Etschmann, and M. Griese Chemokines Indicate Allergic Bronchopulmonary Aspergillosis in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., June 15, 2006; 173(12): 1370 - 1376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Sorensen, J. Madsen, K. Kejling, I. Tornoe, O. Nielsen, P. Townsend, F. Poulain, C. H. Nielsen, K. B. M. Reid, S. Hawgood, et al. Surfactant protein D is proatherogenic in mice Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2286 - H2294. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Sorensen, J. v. B. Hjelmborg, K. O. Kyvik, M. Fenger, A. Hoj, C. Bendixen, T. I. A. Sorensen, and U. Holmskov Genetic and environmental influences of surfactant protein D serum levels Am J Physiol Lung Cell Mol Physiol, May 1, 2006; 290(5): L1010 - L1017. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. A. Al-Salmi, J. N. Walter, G. N. Colasurdo, M. M. Sockrider, E. O. Smith, H. Takahashi, and L. L. Fan Serum KL-6 and Surfactant Proteins A and D in Pediatric Interstitial Lung Disease Chest, January 1, 2005; 127(1): 403 - 407. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
